Compare iShares China Large-Cap ETF (FXI) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Smith & Nephew plc — how do they compare? iShares China Large-Cap ETF trades at $34.59, while Smith & Nephew plc trades at $31.2 (market cap $12.81B). The key difference: Smith & Nephew plc pays a 2.54% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals.
| FXI | SNN | |
|---|---|---|
52-Week High | $41.75 | $38.70 |
52-Week Low | $31.59 | $28.73 |
Market Cap | — | $12.81B |
Sector | — | Health |
Enterprise Value | — | $15.58B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares China Large-Cap ETF (FXI) trades at $34.535, up 2.27% on the day, with technical indicators showing a bullish overall signal despite some overbought RSI readings. Recent news highlights China's significant push into AI and electric vehicles, including a reported $295 billion AI infrastructure plan and a 30% NEV fleet target by 2030, which could benefit the large-cap Chinese companies held within the fund.
The outlook for FXI is tied to China's economic policy execution and its success in strategic sectors like AI and EVs. Key opportunities include exposure to state-backed industrial and tech giants, while risks stem from U.S.-China tech rivalry, regulatory shifts, and the potential for Chinese equities to act as a value trap despite apparent undervaluation.
Smith & Nephew (SNN) trades at $29.83, down 4.02% today, with a bearish technical signal. The company reported revenue of $5.81 billion in 2024, with net income of $412 million, showing improved profitability. Recent news highlights product launches in robotics and wound care, supported by a $500 million share buyback. Analyst consensus is mixed, with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility.
Outlook is balanced: strong free cash flow and innovation in medical technology offer growth potential, but near-term risks include competitive pressures and debt levels. The stock's valuation at a P/E of 21.51 is reasonable if earnings growth sustains, yet technical weakness suggests caution. Investors should weigh solid fundamentals against market sentiment and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
